TheBrief

Digitalis glycosides were associated with fewer worsening heart failure events, but the 2026 evidence did not show a significant reduction in cardiovascular mortality. The findings support selective use as additional therapy in some patients whose heart failure remains symptomatic or continues to worsen despite contemporary treatment.

The benefit was fewer worsening heart failure events

A 2026 meta-analysis concluded that digitalis glycosides reduced the composite risk of cardiovascular death or worsening heart failure compared with control. The practical qualification is important: the composite benefit was driven mainly by fewer worsening heart failure events, not a statistically established reduction in cardiovascular death.

That distinction changes how the result should be discussed. Digitalis should not be presented as a therapy that prolongs survival on the strength of this analysis. Its potential value is narrower—reducing clinical deterioration and the need for urgent heart failure care in appropriately selected patients.

For clinicians, preventing decompensation is still meaningful. Worsening heart failure can lead to emergency treatment, hospitalization, declining functional status and interruption of otherwise beneficial therapy. For health systems, recurrent admissions carry substantial clinical and resource consequences. A treatment does not need to reduce mortality to offer value, but the expected morbidity benefit must be weighed against toxicity and monitoring burdens.

The direction of the meta-analysis is consistent with the landmark Digitalis Investigation Group trial. That randomized trial assigned 6,800 patients with heart failure and left ventricular ejection fraction of 45% or less, who were in sinus rhythm, to digoxin or placebo on top of the standard therapy available at the time. Over an average follow-up of 37 months, digoxin did not reduce overall mortality, but it lowered hospitalization for worsening heart failure.

Outcome in the Digitalis Investigation Group trial	Digoxin	Placebo	Relative effect
Death from any cause	34.8%	35.1%	Risk ratio 0.99; 95% CI, 0.91–1.07
Hospitalization for worsening heart failure	26.8%	34.7%	Risk ratio 0.72; 95% CI, 0.66–0.79

These older findings should not be treated as a direct estimate of benefit under current care. Background treatment in the 1990s did not include the full contemporary regimen of angiotensin receptor–neprilysin inhibitors, sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists and evidence-based beta-blockers now used for heart failure with reduced ejection fraction.

What the meta-analysis adds

By combining randomized evidence across digitalis glycosides, the meta-analysis provides a broader estimate than any single trial and asks whether the class retains clinical value. The comparison was digitalis-based treatment versus control or placebo in people with heart failure, with cardiovascular death and worsening heart failure assessed separately as well as within composite outcomes.

The analysis strengthens the case that the clearest effect of digitalis is on heart failure morbidity. It does not show that the drugs modify the disease process in the same way as therapies with demonstrated mortality benefits. Nor does a favorable composite endpoint permit the assumption that every component improved. When one component—worsening heart failure—accounts for most of the difference, the composite should be interpreted through that component.

This is particularly relevant because events within a composite are not clinically equivalent. Avoiding hospitalization matters, but it is not interchangeable with preventing cardiovascular death. Absolute event rates, follow-up duration and the definition of worsening heart failure also affect how readily a pooled relative effect can be translated to present-day practice.

The analysis concerns a drug class rather than a guarantee of identical effects across agents. Digoxin is the digitalis glycoside most familiar in US practice, while evidence involving other glycosides may not transfer perfectly because pharmacokinetics, elimination and therapeutic monitoring differ. Class-level conclusions therefore require drug-specific judgment.

A possible role after foundational therapy

The evidence supports considering digitalis as an adjunct for selected patients with symptomatic heart failure with reduced ejection fraction who remain at risk of worsening events despite guideline-directed medical therapy. The 2022 American Heart Association, American College of Cardiology and Heart Failure Society of America guideline states that digoxin might be considered in symptomatic patients despite guideline-directed therapy, or when such therapy cannot be tolerated, to reduce heart failure hospitalizations. This is a weaker recommendation than those for treatments proven to reduce mortality.

Digitalis should not displace foundational therapies. The meta-analysis instead reinforces a residual-risk role: a patient may be receiving tolerated evidence-based therapy yet continue to have symptoms, congestion or recurrent decompensation. In that setting, a potential reduction in worsening events may carry greater value than it would for a stable patient with low near-term hospitalization risk.

Selection remains inseparable from safety. Digoxin has a narrow therapeutic window, and toxicity risk rises when clearance falls or susceptibility increases. Kidney function, age, body composition, electrolyte disturbances, conduction disease and interacting medicines can all alter risk. Hypokalemia and hypomagnesemia may increase vulnerability to arrhythmias, while renal impairment can increase exposure.

Clinically important toxicity may include gastrointestinal symptoms, neurologic or visual disturbances, bradycardia and atrial or ventricular arrhythmias. These manifestations are not always specific, especially in older adults with multimorbidity. The practical burden includes medication review, renal and electrolyte assessment, and selective measurement of serum concentrations when clinically appropriate.

Why the evidence does not settle routine use

Meta-analysis can improve precision, but it cannot erase differences among the underlying trials. Studies of digitalis span different eras of heart failure care, drugs, populations, endpoint definitions and follow-up periods. Older trials may overestimate the incremental benefit available after contemporary multidrug therapy, while more recent trials may have fewer events or less power for mortality.

The mortality finding also requires restraint. Failure to demonstrate a reduction in cardiovascular death is not proof that the true effect is exactly zero, but it means a survival claim is unsupported. Conversely, a reduction in worsening heart failure does not by itself resolve concerns about arrhythmias, drug accumulation or treatment discontinuation.

Generalizability may be limited for patients with advanced kidney disease, marked conduction abnormalities, substantial frailty or complex polypharmacy because these groups can face greater toxicity and may be underrepresented in trials. The supplied bibliographic record did not provide enough detail to independently characterize funding and author conflicts; those disclosures should be reviewed in the full publication.

The central trade-off is therefore clearer, not eliminated. Digitalis glycosides may reduce deterioration requiring clinical intervention, but their value depends on baseline event risk, the adequacy of foundational treatment and the feasibility of safe monitoring. That favors selective reconsideration rather than broad revival.

Questions clinicians ask

Does this evidence show that digitalis improves survival?

No. The reported composite benefit was driven mainly by fewer worsening heart failure events, while cardiovascular death was not significantly reduced. Digitalis should therefore be framed as a possible morbidity-reducing adjunct, not as a substitute for therapies with established cardiovascular or all-cause mortality benefits.

Which patients are most likely to be considered?

The evidence is most relevant to selected patients with symptomatic heart failure with reduced ejection fraction who continue to worsen despite tolerated guideline-directed therapy, or who cannot tolerate parts of that regimen. Potential benefit is more compelling when hospitalization risk is substantial and renal function, electrolytes, interactions and rhythm can be monitored.

Does the meta-analysis support routine digitalis use?

No. Differences among trials, treatment eras and individual glycosides limit a universal class recommendation. The absence of a demonstrated cardiovascular mortality benefit, combined with a narrow therapeutic window, supports individualized use after foundational therapy rather than routine initiation across the heart failure population.

What safety issues matter most before selection?

Renal function, potassium and magnesium levels, baseline conduction disease, heart rate and interacting medicines are central considerations. Older age, low body mass, impaired kidney clearance and polypharmacy can increase exposure or susceptibility to toxicity, making the expected reduction in worsening events less attractive when monitoring is difficult.